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Abstract
Background: The	antiphospholipid	syndrome	 (APS)	 is	characterized	by	 thrombosis	
and/or	 pregnancy	 morbidity	 with	 the	 persistent	 presence	 of	 lupus	 anticoagulant	
(LAC),	anti‐cardiolipin	 (aCL)	and/or	anti‐β2glycoprotein	I	 (aβ2GPI)	antibodies	of	the	
immunoglobulin	G/immunoglobulin	M	(IgG/IgM)	isotype.	However,	the	role	of	aCL	
and aβ2GPI	IgM	as	a	serologic	marker	in	APS	is	debated.
Objectives: We	aimed	to	assess	the	diagnostic	and	clinical	value	of	IgM	antiphospho‐
lipid	antibodies	(aPL)	in	APS	within	the	classification	criteria.
Patients/Methods: Our	multicenter	study	comprised	1008	patients,	 including	APS	
patients	 and	 controls.	Anti‐CL	and	aβ2GPI	 IgG	and	 IgM	antibodies	were	detected	
with	four	commercially	available	solid	phase	assays.
Results: Positivity	for	aCL	and/or	aβ2GPI	antibodies	was	significantly	correlated	with	
thrombosis	 and	 pregnancy	 morbidity,	 independent	 of	 the	 isotype	 and	 solid	 phase	
assay.	Higher	odds	ratios	were	obtained	for	IgG	compared	to	IgM	positivity.	Isolated	
IgM	was	rare	in	thrombotic	APS,	but	more	frequent	in	obstetric	APS,	ranging	from	3.5%	
to	5.4%	and	5.7%	to	12.3%,	respectively,	dependent	on	the	solid	phase	assay.	In	a	mul‐
tivariate	logistic	regression	analysis	of	aPL,	IgM	positivity	was	found	to	be	associated	
with	pregnancy	morbidity.	However,	detection	of	IgM	was	not	independently	associ‐
ated	with	thrombosis.	Combined	positivity	for	LAC,	IgG,	and	IgM	was	highly	associated	
with	thrombosis	and	pregnancy	morbidity.
Conclusions: Our	data	support	testing	for	aCL	and	aβ2GPI	IgM	in	women	suspected	
of	obstetric	APS.	However,	 no	 added	value	was	 found	 for	 testing	 IgM	 in	patients	
suspected	of	thrombotic	APS.	Still,	IgM	aPL	might	be	useful	as	a	second‐line	test	to	
improve	thrombotic	risk	stratification.
K E Y W O R D S
antiphospholipid	antibodies,	immunoassays,	immunoglobulin	isotypes,	pregnancy	morbidity,	
thrombosis
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1  | INTRODUC TION
The	 antiphospholipid	 syndrome	 (APS)	 is	 characterized	 by	 throm‐
bosis	 and/or	pregnancy	morbidity	with	 the	persistent	presence	of	
antiphospholipid	 antibodies	 (aPL).1	 Obstetrical	 complications	 in‐
clude	 fetal	 loss	 after	 the	 10th	 week	 of	 gestation,	 recurrent	 early	
miscarriages	 and	 premature	 birth	 due	 to	 severe	 preeclampsia,	 or	
intrauterine growth restriction.1	 Thrombotic	 APS	 is	 characterized	
by	 venous,	 arterial,	 and/or	 small	 vessel	 thrombosis.1	 Diagnosis	 of	
APS	predominantly	relies	on	aPL	assays	detecting	lupus	anticoagu‐
lant	(LAC)	by	a	functional	assay	or	detection	of	anti‐cardiolipin	(aCL)	
immunoglobulin	 G/immunoglobulin	 M	 (IgG/IgM)	 antibodies	 and	
anti‐β2glycoprotein	I	(aβ2GPI)	IgG/IgM	antibodies	by	solid	phase	as‐
says.1‐3	Within	the	current	criteria,	persistent	presence	of	either	IgG	
or	IgM	aPL	with	associated	thrombosis	and/or	pregnancy	morbidity	
is	sufficient	for	the	classification	of	APS.1	However,	the	value	of	IgM	
aCL	and	aβ2GPI	antibodies	in	APS	classification	is	debated.4‐10
Recently	a	meta‐analysis	aimed	to	assess	the	clinical	value	of	IgM	
aCL	and	aβ2GPI	antibodies	in	thrombotic	APS	and	found	a	stronger	
thrombotic	correlation	for	IgG	than	for	IgM	antibodies.4	Studies	that	
found	 a	 statistical	 association	 for	 aCL	 and	 aβ2GPI	 IgM	 antibodies	
with	thrombosis	mostly	also	found	a	significant	association	for	the	
IgG	isotype,	suggesting	a	limited	role	of	IgM	in	thrombotic	APS.4 In 
the	meta‐analysis,	two	studies	were	included	that	found	a	protective	
role	of	 IgM	antibodies	 in	thrombosis.4,11,12	 In	2006,	another	meta‐
analysis	assessed	the	association	between	aCL	antibodies	and	recur‐
rent	fetal	loss	in	women	without	an	autoimmune	disease	and	found	a	
statistical	association	for	both	isotypes	(IgM	and	IgG).6	However,	in	
both	meta‐analyses	authors	were	unable	to	evaluate	IgM	antibodies	
as	 a	 single	 serologic	marker,	 because	 of	 unavailability	 of	 separate	
IgG and IgM results.4,6	In	addition,	comparison	of	clinical	studies	is	
difficult	 as	multiple	 study	designs	are	used	with	a	wide	variety	of	
aPL	assays.	Solid	phase	assays	are	poorly	standardized	and	external	
quality	control	programs	have	shown	that	aPL	assays	produce	vari‐
able results.13,14
More evidence has become available that hints toward evalua‐
tion	of	the	complete	aPL	profile	to	improve	risk	stratification	of	APS	
patients.2,15‐17	In	an	observational	study	among	purely	obstetric	APS	
patients,	aCL	and	aβ2GPI	positivity	together	with	LAC	(triple	positiv‐
ity)	was	a	predictor	of	pulmonary	embolism	while	single	LAC	positiv‐
ity was not.18	Another	study	found	that	the	presence	of	any	aPL	at	
any	time	did	not	result	in	a	significant	increase	in	the	risk	of	throm‐
botic	 recurrence,	 while	 the	 persistent	 presence	 of	 the	 same	 type	
increased	the	risk	of	thrombotic	recurrence	significantly.15	Multiple	
aPL	positivity	at	the	same	time	or	at	different	time	points	even	fur‐
ther	increased	the	risk	of	recurrence.15	We	have	previously	shown	
that	the	thrombotic	association	of	IgM	antibodies	within	triple	posi‐
tive	(positivity	for	LAC,	aCL,	and	aβ2GPI)	patients	is	limited.19	Here,	
we	aimed	to	assess	the	value	of	IgM	antibodies	as	a	single	serologic	
marker	in	APS	and	its	clinical	value	in	aPL	profiles	within	the	current	
classification	criteria.	Four	commercially	available	solid	phase	assays	
were	 used,	 reducing	 assay	 dependency	 on	 the	 association	 of	 IgM	
antibodies	and	thrombosis	or	obstetric	complications.
2  | METHODS
2.1 | Study population
Patient	 samples	were	 collected	 from	 eight	 European	medical	 cent‐
ers	within	a	time	span	of	one	year,	with	patient	samples	stored	less	
than	five	years	at	or	below	‐80°C.	The	Sydney	classification	criteria	
were	 followed	 for	 the	 diagnosis	 of	 thrombotic	 and	 obstetric	 APS.1 
Thrombosis	was	defined	as	one	or	more	clinical	episodes	of	arterial,	
venous,	or	small	vessel	thrombosis,	in	any	tissue	or	organ,	confirmed	
by	objective	validated	criteria	(eg,	unequivocal	findings	of	appropriate	
imaging	studies	or	histopathology).1	Pregnancy	morbidity	was	defined	
as:	 (1)	one	or	more	unexplained	deaths	of	a	morphologically	normal	
fetus	at	or	beyond	the	10th	week	of	gestation,	with	normal	fetal	mor‐
phology	documented	by	ultrasound	or	by	direct	examination	of	the	
fetus;	(2)	one	or	more	premature	births	of	a	morphologically	normal	
neonate	before	the	34th	week	of	gestation	because	of:	eclampsia	or	
severe	preeclampsia	defined	according	 to	 standard	definitions,	 rec‐
ognized	 features	of	placental	 insufficiency;	 (3)	 three	or	more	unex‐
plained	 consecutive	 spontaneous	 abortions	 before	 the	 10th	 week	
of	gestation,	with	maternal	anatomic	or	hormonal	abnormalities	and	
paternal	and	maternal	chromosomal	causes	excluded.1	Patients	were	
classified	as	thrombotic	or	obstetric	APS	by	the	local	center.	Control	
populations	consisted	of	patients	with	an	autoimmune	disease	other	
than	APS	(eg,	systemic	 lupus	erythematosus	and	systemic	sclerosis)	
without	 thrombotic	 complications	 (autoimmune	 disease	 [AID]	 con‐
trols);	patients	 that	were	 referred	 for	aPL	 testing	 for	other	 reasons	
than	 the	clinical	criteria	of	APS	 (eg,	 subfertility	and	prolonged	acti‐
vated	partial	 thromboplastin	 time	 [aPTT],	 controls);	 patients	with	 a	
previous	thrombotic	event	negatively	tested	for	aPL	(non‐APS	throm‐
bosis);	 and	patients	 that	experienced	obstetric	complications	 in	 the	
absence	of	aPL	(non‐APS	obstetric).	The	study	was	approved	by	the	
local ethical committees.
3  | L ABOR ATORY A SSAYS
3.1 | Lupus anticoagulant
Lupus	anticoagulant	assays	were	performed	by	the	local	center,	ac‐
cording	to	the	International	Society	of	Thrombosis	and	Haemostasis‐
Scientific	Standardization	Committee	(ISTH‐SSC)	guideline.20	Briefly,	
citrated	 blood	 was	 double	 centrifuged	 for	 15	 minutes	 at	 2000	 g	
Essentials
•	 The	value	of	IgM	antiphospholipid	antibodies	(aPL)	in	APS	
is debated
•	 Detection	of	IgM	aPL	is	of	added	diagnostic	value	in	ob‐
stetric	but	not	thrombotic	antiphospholipid	syndrome
•	 Detection	of	IgM	aPL	in	patients	positive	for	LAC	and	IgG	
is	useful	for	risk	stratification	in	thrombotic	antiphospho‐
lipid	syndrome
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(room	 temperature).20	After	 transferring	 the	plasma	 in	 a	 non‐acti‐
vating	plastic	centrifuge	tube,	the	plasma	was	centrifuged	for	an	ad‐
ditional	10	minutes	at	>	2500	g	(room	temperature).20	The	obtained	
platelet‐poor	plasma	was	tested	for	a	prolonged	clotting	time	with	
two	tests	based	on	different	principles	(eg,	aPTT	and	dilute	Russell	
viper	venom	time).	Lupus	anticoagulant	testing	was	performed	by	a	
three‐step	procedure	including	screening,	mixing,	and	confirmation.
3.2 | Solid phase assays
Commercially	available	solid	phase	assays	were	selected	based	on	
frequently	 used	 assays	 in	 the	 external	 quality	 control	 program	 of	
the	ECAT	(External	Quality	Control	of	Diagnostic	Assays	and	Tests,	
Voorschoten,	the	Netherlands)	and	the	willingness	of	manufacturers	
for	collaboration.	Anti‐CL	IgG,	aCL	IgM,	aβ2GPI	IgG,	and	aβ2GPI	IgM	
aPL	were	detected	by	four	solid	phase	assays:	BioPlex®2200	(Bio‐
Rad,	Bio‐Rad	Laboratories,	Hercules,	USA),	Phadia®	(Thermo	Fisher	
Scientific/Phadia,	Uppsala,	Sweden),	ACL	AcuStar®	(Instrumentation	
Laboratories,	 Bedford,	 USA)	 and	 QUANTA	 Lite®	 ELISA	 (Inova	
Diagnostics,	 San	 Diego,	 USA)	 in	 the	 Ghent	 University	 Hospital	
(Ghent,	Belgium).	Detection	of	aCL	and	aβ2GPI	antibodies	was	per‐
formed	 according	 to	 manufacturer's	 instructions.	 Manufacturer's	
recommended	 cut‐off	 values	 were	 used	 upon	 confirmation	 in	 20	
healthy	volunteers,	in	accordance	with	the	ISTH‐SSC	guideline.21
3.3 | Statistical analyses
Crude	odds	ratios	for	thrombosis	were	calculated	within	patients	with	
thrombotic	 APS,	 non‐APS	 thrombosis,	 AID	 controls,	 and	 controls.	
Crude	 odds	 ratios	 for	 pregnancy	 morbidity	 were	 calculated	 within	
women	with	obstetric	APS,	non‐APS	obstetric	APS,	normal	pregnancy,	
AID	controls,	and	controls.	Differences	in	IgM	titers	above	the	thresh‐
old	were	assessed	with	the	Mann‐Whitney	U	test.	In	a	multivariate	lo‐
gistic	regression	analysis,	a	backward	variable	selection	was	performed	
with variables having a P‐value	<	0.2.	In	order	to	evaluate	independent	
variables	for	thrombosis,	analysis	was	performed	on	the	total	popula‐
tion	with	a	model	including	age,	sex,	pregnancy	morbidity,	LAC,	IgG,	
and	 IgM.	Within	women,	 age,	 thrombosis,	 LAC,	 IgG,	 and	 IgM	were	
included	in	the	multivariate	model	to	evaluate	independent	variables	
for	pregnancy	morbidity.	Odds	ratios	with	their	respective	95%	confi‐
dence	interval	were	determined	for	each	variable	in	the	final	model.	A	
P‐value	<	0.05	was	regarded	as	statistically	significant.	Statistical	anal‐
yses	were	performed	using	the	statistical	package	for	social	sciences	
(SPSS	23.0;	SPSS,	New	York,	USA)	and	MedCalc	Statistical	Software	
version	17.7.2	(MedCalc	Software	bvba,	Ostend,	Belgium).
4  | RESULTS
4.1 | Patient characteristics
We	included	1008	patients	of	whom	75.7%	were	female	with	a	mean	
age	of	44	years	 (Table	1).	Venous	 thrombosis	was	more	prevalent	
compared	 to	 arterial	 thrombosis	 in	 thrombotic	 APS	 and	 non‐APS	 T
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thrombosis	patients,	62%	and	73%,	respectively	(Table	1).	The	ma‐
jority	of	thrombotic	APS	patients	received	anticoagulant	therapy	in‐
cluding	vitamin	K	antagonists	(46%),	low	molecular	weight	heparins	
(5%),	 and	 direct	 oral	 anticoagulants	 (4%).	 Twenty‐seven	 patients	
(10%)	received	antiplatelet	therapy	and	2%	of	patients	with	throm‐
botic	 APS	 received	 both	 anticoagulant	 and	 antiplatelet	 therapy.	
Details	on	anticoagulant	and	antiplatelet	 therapy	of	 the	 remaining	
84	patients	were	not	available.
4.2 | Diagnostic role of aCL and aβ2GPI IgG/IgM 
antibodies in thrombosis
Lupus	 anticoagulant	 positivity	 resulted	 in	 an	 odds	 ratio	 (OR)	 for	
thrombosis	 of	 3.4	 (95%	 confidence	 interval	 [95%	 CI],	 2.5‐4.7)	
(Table	2).	Positivity	for	aCL	or	aβ2GPI	antibodies	was	significantly	as‐
sociated	with	thrombosis,	independent	of	the	isotype	or	solid	phase	
assay	used	(Table	2).	Positivity	for	IgG	aCL	or	aβ2GPI	antibodies	was	
more	strongly	correlated	with	thrombosis	than	IgM	aCL	or	aβ2GPI	
antibodies	 (Table	2).	 Lupus	 anticoagulant,	 IgG	 aCL	or	 aβ2GPI,	 and	
IgM	aCL	or	aβ2GPI	were	analyzed	in	a	multivariate	model	in	which	
IgM	 aCL	 or	 aβ2GPI	 antibodies	 resulted	 not	 to	 be	 an	 independent	
variable	for	thrombosis,	independent	of	the	solid	phase	assay	used.	
In	addition,	we	performed	a	subanalysis	separately	on	patients	with	
venous	or	arterial	thrombosis	in	which	IgM	aCL	or	aβ2GPI	antibodies	
were	not	an	independent	variable	for	both	types	of	thrombosis	(data	
not	shown	for	the	separate	subpopulations).	Within	the	multivariate	
model,	lupus	anticoagulant	and	IgG	aCL	or	aβ2GPI	antibodies	were	
independent	variables	with	OR	between	2.3	(95%CI,	1.6‐3.3)	and	2.4	
(95%CI,	1.7‐3.4)	and	2.3	 (95%CI,	1.6‐3.5)	and	3.2	 (95%CI,	2.0‐5.0),	
respectively	(Table	2).
4.3 | Diagnostic role of aCL and aβ2GPI IgG/IgM 
antibodies in pregnancy morbidity
Similar	to	thrombosis,	positivity	for	aCL	or	aβ2GPI	antibodies	was	
significantly	associated	with	pregnancy	morbidity,	independent	of	
the	isotype	or	solid	phase	assay	used	(Table	3).	Positivity	for	IgG	
aCL	or	aβ2GPI	antibodies	clearly	resulted	in	higher	crude	OR	for	
obstetric	complications	than	positivity	for	IgM	aCL	or	aβ2GPI	an‐
tibodies	 (Table	3).	 In	 contrast	 to	 thrombosis,	 IgM	aCL	or	aβ2GPI	
antibodies	 was	 an	 independent	 variable	 for	 pregnancy	 morbid‐
ity	with	OR	 ranging	between	1.7	 (95%	CI,	 1.1‐2.8)	 and	2.0	 (95%	
CI,	 1.1‐3.5).	 The	OR	 of	 LAC	 positivity	 varied	 between	 3.6	 (95%	
CI,2.3‐5.7)	and	3.9	(95%	CI,	2.5‐6.1)	(Table	3).	IgG	aCL	or	aβ2GPI	
antibodies	was	an	independent	variable	with	three	out	of	the	four	
tested	 solid	 phase	 assays,	 resulting	 in	OR	between	1.9	 (95%	CI,	
1.1‐3.2)	and	2.5	(95%	CI,	1.5‐4.4).
4.4 | Additional diagnostic value of aCL and aβ2GPI 
IgM antibodies in thrombotic patients
Positivity	 for	 IgM	 aCL	 or	 aβ2GPI	 antibodies	 ranged	 from	 26%	 to	
36%	among	thrombotic	APS	patients,	0%	to	3.4%	among	non‐APS	T
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thrombosis	patients,	and	6.4%	to	16%	among	patients	with	an	au‐
toimmune	disease	and	controls	(Table	4).	Thrombotic	APS	patients	
with	isolated	IgM	aCL	or	aβ2GPI	positivity	ranged	from	3.5%	to	5.4%	
(Table	4).	 In	addition,	up	to	2.5%	of	patients	classified	as	non‐APS	
thrombosis	were	found	to	be	isolated	positive	for	IgM	aCL	or	aβ2GPI	
antibodies	(Table	4).	The	prevalence	of	isolated	IgM	aCL	or	aβ2GPI	
antibodies	in	controls	and	AID	patients	was	1.8%	to	10%	as	detected	
by	BioPlex®2200	and	Phadia®,	respectively	(Table	4).
4.5 | Additional diagnostic value of aCL and aβ2GPI 
I IgM antibodies in patients with pregnancy morbidity
Positivity	for	IgM	aCL	or	aβ2GPI	antibodies	ranged	from	21%	to	34%	
among	obstetric	APS	patients,	0%	to	9.1%	among	non‐APS	obstetric	
patients	(Table	2),	and	6.4%	to	16%	among	female	patients	with	an	
autoimmune	disease	and	controls.	Isolated	IgM	aCL	or	aβ2GPI	posi‐
tivity	ranged	from	5.7%	to	12.3%	in	APS‐obstetric	patients	(Table	2).	
Up	to	6%	of	the	patients	classified	as	non‐APS	obstetric	were	found	
to	be	isolated	positive	for	IgM	aCL	or	aβ2GPI	and	up	to	10%	of	fe‐
male	patients	with	an	autoimmune	disease	and	controls	were	only	
positive	for	IgM	aCL	or	aβ2GPI	antibodies	but	not	LAC	or	IgG	aCL	or	
aβ2GPI	antibodies.
4.6 | IgM antibody titers in thrombotic 
patients and controls
Positive	IgM	aCL	or	aβ2GPI	antibody	titers	were	compared	between	
patients	with	thrombosis	and	controls	(AID	and	control)	within	one	
solid	 phase	 assay.	No	 significant	 difference	 in	 IgM	 aCL	 or	 aβ2GPI	
antibody	 titers	 was	 found	 between	 patients	 with	 thrombosis	 and	
our	control	population	with	the	exception	of	one	solid	phase	assay	
(Phadia®)	(Figure	1A).
4.7 | IgM antibody titers in obstetric 
patients and controls
IgM	aCL	or	aβ2GPI	antibody	titers	were	not	significantly	different	be‐
tween	patients	with	pregnancy	morbidity	and	the	control	population	
with	all	solid	phase	assays	tested	(Figure	1B).	Of	note,	maximum	IgM	
aCL	or	aβ2GPI	antibody	titers	measured	were	higher	in	thrombotic	
patients	versus	obstetric	patients:	3708	versus	995	(BioPlex®2200),	
1056	versus	410	(Phadia®),	2798	versus	785	(ACL	AcuStar®),	and	320	
versus	250	(QUANTA	Lite®	ELISA)	of	the	respective	units.
4.8 | Additional clinical value of aCL and aβ2GPI I 
IgM antibodies in thrombotic patients
Within	the	current	criteria	positivity	for	either	LAC,	IgG	aCL/aβ2GPI,	
or	IgM	aCL/aβ2GPI	is	sufficient	for	classification	of	APS.	In	our	co‐
hort,	 these	classification	criteria	 resulted	 in	OR	between	2.4	 (95%	
CI,	 1.8‐3.2)	 and	2.9	 (95%	CI,	 2.2‐3.9)	 (Table	 5).	 Combined	positiv‐
ity	for	LAC	and	IgG	aCL	or	aβ2GPI	antibodies	resulted	in	higher	OR	
than	combined	positivity	for	LAC	and	IgM	aCL	or	aβ2GPI	antibodies	TA
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with	two	out	of	the	four	tested	solid	phase	assays.	With	the	other	
solid	 phase	 assays,	 combined	 positivity	 for	 LAC	 and	 IgM	 aCL	 or	
aβ2GPI	reached	higher	OR	than	positivity	 for	LAC	and	 IgG	aCL	or	
aβ2GPI.	The	variation	 in	OR	for	thrombosis	among	solid	phase	as‐
says	increased	in	combined	positivity	for	IgG	aCL	or	aβ2GPI	and	IgM	
aCL	or	aβ2GPI	antibodies	from	2.6	(95%	CI,	1.6‐4.5)	up	to	7.1	(95%	
CI,	 3.0‐16.7)	 (Table	 5).	 The	 combination	 of	 positive	 LAC,	 IgG	 aCL	
or aβ2GPI,	and	IgM	aCL	or	aβ2GPI	results	is	highly	associated	with	
thrombosis	with	OR	between	5.5	(95%	CI,	2.6‐11.8)	and	9.6	(95%	CI,	
3.4‐27.1)	(Table	5).
4.9 | Additional clinical value of aCL and aβ2GPI 
IgM antibodies in patients with pregnancy morbidity
Positivity	for	either	LAC,	IgG	and/or	IgM	antibodies	resulted	in	OR	
between	4.9	(95%	CI,	3.2‐7.4)	and	6.6	(95%CI,	4.3‐10.0)	(Table	6).	In	
contrast	to	thrombosis,	combined	positivity	for	LAC	and	IgG	aCL	or	
aβ2GPI	or	LAC	and	IgM	aCL	or	aβ2GPI	antibodies	did	not	increase	
the	association	with	pregnancy	morbidity	compared	to	the	classifi‐
cation	criteria	(Table	6).	Positivity	for	LAC	and	IgG	aCL	or	aβ2GPI	an‐
tibodies	resulted	in	OR	between	2.5	(95%	CI,	1.5‐4.2)	and	4.3	(95%	
CI,	2.2‐8.6)	(Table	6).	Positivity	for	LAC	and	IgM	aCL	or	aβ2GPI	anti‐
bodies	resulted	in	OR	between	2.7	(95%	CI,	1.3‐5.6)	and	3.5	(95%	CI,	
1.5‐8.3)	(Table	6).	The	association	between	pregnancy	morbidity	and	
LAC,	IgG	and/or	IgM	aCL,	or	aβ2GPI	positivity	were	similar	(Table	6).	
However,	positivity	for	 IgG	aCL	or	aβ2GPI	and	IgM	aCL	or	aβ2GPI	
antibodies	resulted	in	a	large	variation	of	OR	for	pregnancy	morbid‐
ity	 among	 solid	 phase	 assays.	 Combined	 positivity	 for	 IgG	 aCL	 or	
aβ2GPI	and	IgM	aCL	or	aβ2GPI	antibodies	resulted	in	OR	between	
2.7	(95%	CI.	1.4‐5.2)	and	8.0	(95%	CI,	3.1‐20.2).	IgM	aCL	or	aβ2GPI	
positivity	in	combination	with	LAC	and	IgG	aCL	or	aβ2GPI	positivity	
is	highly	associated	with	pregnancy	morbidity	with	OR	between	4.9	
(95%	CI,	2.0‐12.3)	and	8.7	(95%	CI,	2.8‐26.6).
5  | DISCUSSION
The	 role	 of	 IgM	aCL	or	 aβ2GPI	 antibodies	 as	 a	 serologic	marker	
in	APS	 is	debated.1,4,7,8,22	Although	most	 studies	were	unable	 to	
demonstrate	an	association	between	IgM	aCL	or	aβ2GPI	antibod‐
ies	and	thrombosis,	a	questionnaire	by	the	SSC	of	the	ISTH	indi‐
cated	that	most	of	the	respondents	found	it	too	early	to	eliminate	
IgM	aCL	or	aβ2GPI	antibodies	from	the	criteria.8 We demonstrated 
a	significant	correlation	for	both	IgG	and	IgM	aCL	and	aβ2GPI	anti‐
bodies	with	thrombosis	as	well	as	pregnancy	morbidity.	However,	
IgM	positivity	was	mostly	associated	with	positivity	for	LAC	and/
or	IgG	aPL.	The	presence	of	isolated	IgM	antibodies	in	thrombotic	
APS	patients	was	rare	(3.5%‐5.4%,	Table	4),	and	not	an	independ‐
ent	variable	 for	 thrombosis.	 In	 addition,	 IgM	aCL	or	 aβ2GPI	was	
not	 found	 to	be	an	 independent	variable	 for	 arterial	 nor	venous	
thrombosis.	These	results	are	in	line	with	prospectively	collected	
data	from	patients	referred	to	Italian	thrombosis	centers	in	which	
only	a	minority	of	APS	patients	was	found	to	be	positive	for	pre‐
dominantly	aCL	or	aβ2GPI	IgM	antibodies	(>40	MPL	units	and	<	40	
GPL	units).16	A	thrombotic	association	of	true	isolated	IgM	has	not	
been	 reported	 in	 literature.	One	study	concluded	 that	 “isolated”	
IgG	antibodies	are	more	prevalent	in	deep	venous	thrombosis	and	
pulmonary	 embolism	 while	 “isolated”	 aCL	 IgM	 antibodies	 were	
frequently	 found	 in	patients	with	 a	 cerebrovascular	 infarction.23 
However,	patients	were	only	tested	for	aCL	and	aβ2GPI	IgG/IgM	
antibodies	 and	 not	 for	 LAC,	 rendering	 the	 identification	 of	 true	
isolated	 IgG	 or	 IgM	 antibodies	 impossible.23 While we showed 
that	 IgM	 was	 not	 an	 independent	 variable	 of	 thrombosis	 along	
with	LAC	and	IgG,	another	study	even	found	that	in	SLE	patients	
aβ2GPI	IgM	antibodies	were	protective	against	lupus	nephritis	and	
renal damage.24
Within	 the	current	 aPL‐panel,	 LAC	 is	 considered	 the	 strongest	
predictor	 of	 thrombosis	 and	 pregnancy	 morbidity.25,26	 In	 2003,	
a	 meta‐analysis	 assessed	 the	 role	 of	 LAC	 and	 aCL	 antibodies	 in	
F I G U R E  1  Titers	of	patients	with	thrombosis	or	pregnancy	
morbidity	positive	for	IgM	antibodies	versus	controls	(autoimmune	
disease	and	controls)	positive	for	IgM	antibodies.	Log	transformed	
IgM	titers	of	patients	with	(A)	thrombosis	or	(B)	pregnancy	
morbidity	are	indicated	in	red	and	patients	without	the	clinical	
criteria	for	APS	are	indicated	in	black.	Titers	are	expressed	as	the	
median	value	of	positive	IgM	titers	with	their	95%	confidence	
interval. *P‐value	<	.05.	NS,	not	significant;	AU,	arbitrary	units
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thrombosis.	Computed	ORs	 for	both	LAC	and	aCL	positivity	were	
only	available	in	five	studies,	of	which	none	was	able	to	illustrate	a	
significant	association	between	thrombosis	and	IgG	or	IgM	aCL	anti‐
bodies.26	We	found	an	association	between	LAC	as	well	as	aCL	anti‐
bodies	and	thrombosis,	independent	of	the	isotype	and	solid	phase	
assay	used.	As	argued	by	de	Groot	et	al	most	of	the	studies	included	
in	the	meta‐analysis	did	not	follow	the	ISTH‐SSC	guidelines,	in	which	
it	is	stated	that	aCL	antibodies	should	bind	to	cardiolipin	in	a	β2GPI‐
dependent	 manner.1,3,27‐29	 A	 more	 recent	 meta‐analysis	 included	
studies	 between	2001	 and	2014	 and	 showed	 that	 aCL	 antibodies	
are	 associated	with	 thrombosis,	 especially	 aCL	 IgG	 antibodies.4 In 
our	cohort,	LAC	was	an	independent	variable	for	thrombosis,	illus‐
trating	its	 importance	in	thrombotic	APS.	In	addition,	LAC	showed	
the	highest	association	with	pregnancy	morbidity	within	the	current	
aPL	panel.
Thrombotic	and	obstetric	APS	are	hypothesized	to	have	a	dis‐
tinct	aPL	profile	with	more	 frequent	 IgM	positivity	 in	obstetrical	
APS.30	Our	results	suggest	comparable	IgM	positivity	in	obstetrical	
APS	to	thrombotic	APS,	21%‐34%	and	26%‐36%,	respectively	(de‐
pendent	on	the	solid	phase	assay).	However,	LAC,	aCL,	and	aβ2GPI	
IgG/IgM	 antibodies	 were	 found	 to	 be	 independently	 associated	
with	pregnancy	morbidity.	In	contrast,	IgM	was	not	independently	
associated	 with	 thrombosis.	 In	 agreement,	 a	 systematic	 review	
and	meta‐analysis	found	a	significant	association	of	LAC,	aCL	IgG/
IgM,	and	aβ2GPI	 IgG/IgM	antibodies	with	preeclampsia	and	fetal	
death.31	 Another	 study	 found	 that	 positivity	 for	 LAC,	 aCL	 IgG,	
and	aCL	 IgM	were	associated	with	 recurrent	 fetal	 loss	 in	women	
without autoimmune disease.6	 In	 the	 same	 study,	 no	 significant	
association	 was	 found	 between	 aβ2GPI	 positivity	 and	 recurrent	
loss,	presumably	due	to	the	small	study	population.6	 In	a	popula‐
tion‐based,	case‐control	study,	aPL	were	measured	in	582	stillbirth	
deliveries and 1547 live birth deliveries.32 Women with a stillbirth 
were	 found	 to	 be	more	 likely	 to	 have	 elevated	 aCL	 and	 aβ2GPI	
IgG	levels,	but	not	aCL	and	aβ2GPI	IgM	levels	compared	to	those	
with term live births.32	We	found	a	significant	association	between	
aCL	 IgM	or	aβ2GPI	 IgM	antibodies	and	pregnancy	morbidity,	but	
were	 not	 able	 to	 differentiate	 in	 subgroups	due	 to	 unavailability	
of	detailed	description	of	obstetric	complications.	The	PROMISSE	
(Predictors	of	Pregnancy	Outcome:	Biomarkers	in	Antiphospholipid	
Antibody	Syndrome	and	Systemic	Lupus	Erythematosus)	study	has	
shown	 that	 LAC	 is	 the	 primary	 predictor	 of	 obstetric	 complica‐
tions	after	12	weeks	of	gestation	in	aPL	associated	pregnancies.25 
TA B L E  4  Additional	diagnostic	value	of	aCL	and	aβ2GPI	IgM	antibodies
  
Overall popula‐
tion (n = 1008)
Non‐APS 
thrombosis 
(n = 204)
APS‐thrombo‐
sis (n = 259)
Non‐APS 
obstetric 
(n = 33)
APS‐ obstetric 
(n = 122) AID (n = 196)
Controls 
(n = 194)
LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG
A
  + − + − + − + − + − + − + −
IgM + 95 23 0 0 58 9 0 0 19 7 12 6 6 1
 − 304 586 3 201 157 35 0 33 72 24 56 122 16 171
Total  399 609 3 201 215 44 0 33 91 31 68 128 22 172
B
  + − + − + − + − + − + − + −
IgM + 135 72 2 5 80 14 1 2 30 12 15 25 7 14
 − 273 528 10 187 136 29 1 29 62 18 51 105 13 160
Total  408 600 12 192 216 43 2 31 92 30 66 130 20 174
C
  + − + − + − + − + − + − + −
IgM + 123 37 0 1 71 10 0 1 24 9 21 10 7 6
 − 294 554 7 196 153 25 0 32 70 19 50 115 14 167
Total  417 591 7 197 224 35 0 33 94 28 71 125 21 173
D
  + − + − + − + − + − + − + −
IgM + 113 56 0 1 70 14 0 2 24 15 15 19 4 5
 − 276 563 5 198 143 32 1 30 66 17 47 115 14 171
Total  389 619 5 199 213 46 1 32 90 32 62 134 18 176
Note: Figures	indicate	the	number	of	patients	testing	positive	or	negative	for	IgM	antibodies	or	LAC/IgG.	A	BioPlex®2200 B,	Phadia® C	ACL	AcuStar® 
and D	QUANTA	Lite®	ELISA.
AID,	autoimmune	disease;	APS,	antiphospholipid	syndrome;	IgG	antibodies,	aCL,	or	aβ2GPI	IgG	antibodies;	IgM	antibodies,	aCL,	or	aβ2GPI	IgM	anti‐
bodies;	LAC,	lupus	anticoagulant.
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Positivity	 for	aCL	and	aβ2GPI	antibodies	did	not	predict	adverse	
pregnancy	outcomes	 if	 LAC	was	 absent.25	 In	 contrast,	we	 found	
that	positivity	for	aCL	and	aβ2GPI	IgG	and	IgM	were	independently	
associated	with	a	history	of	pregnancy	morbidity.	However,	 LAC	
showed	 the	highest	association	with	pregnancy	morbidity	within	
the	current	aPL‐panel.	In	addition,	the	presence	of	isolated	IgM	an‐
tibodies	in	obstetric	APS	patients	was	rare	(5.7%‐12.3%,	Table	4),	
dependent	on	the	solid	phase	assay.
Some	studies	found	a	strong	correlation	of	high	aPL	titers	with	
clinical	manifestations	of	APS.9,33‐35	However,	 previous	 reports	 on	
the	 association	 between	 aPL	 titers	 and	 pregnancy	 morbidity	 are	
conflicting.32,36,37	In	a	retrospective	study	a	higher	cut‐off	value	did	
not result in a stronger association with stillbirth.32	Another	 study	
assessed	whether	there	is	a	relationship	between	low	aPL	levels	and	
obstetrical	complications.36	The	authors	found	that	patients	with	low	
aPL	titers	have	similar	obstetrical	outcomes	compared	to	confirmed	
APS	patients.36	 In	 contrast,	 the	 risk	of	adverse	 fetal/neonatal	out‐
come	was	found	to	be	higher	 in	APS‐obstetrical	patients	with	high	
aPL	titers	(≥4	times	upper	limit	of	normal)	compared	to	APS‐obstetri‐
cal	patients	with	aPL	titers	<	4	times	the	upper	limit	of	normal.37 Our 
results	 showed	 that	 IgM	 titers	were	not	 significantly	 different	 be‐
tween	obstetrical	patients	and	our	control	population.	Of	note,	the	
maximum	 IgM	titer	measured	 in	obstetric	patients	was	 lower	 than	
the	maximum	 titers	 measured	 in	 thrombotic	 patients.	 In	 addition,	
patients	with	a	history	of	thrombosis	did	not	have	significant	differ‐
ently	IgM	titers	than	patients	without	thrombosis.	Future	studies	are	
needed	to	investigate	the	relationship	between	aPL	titers	and	clinical	
manifestation	of	APS	in	more	detail.	Categorizing	aPL	titers	into	low,	
medium,	and	high	positivity	might	help	to	study	the	correlation	be‐
tween	aPL	titers	and	thrombosis	or	pregnancy	morbidity.
In	APS,	multiple	aPL	positivity	(aPL	profiles)	have	shown	to	be	of	
added	value	in	thrombotic	risk	stratification.15,17,38	In	agreement,	we	
found	that	OR	for	thrombosis	were	highest	in	patients	positive	for	
LAC,	IgG,	and	IgM.	One	study	assessed	the	role	of	aβ2GPI	and	aCL	
antibodies	in	87	LAC‐positive	patients	and	found	that	the	presence	
of	IgG	but	not	IgM	antibodies	in	LAC	positives	predicts	an	increased	
TA B L E  5  Additional	value	of	aCL	and	aβ2GPI	IgM	antibodies	in	thrombosis
 BioPlex®2200 Phadia® AcuStar® QUANTA Lite® ELISA
LAC	and/or	IgG	and/or	IgM 2.9	(2.2‐3.9)
n = 324
2.4	(1.8‐3.2)
n = 372
2.9	(2.1‐3.8)
n = 350 
2.8	(2.1‐3.7)
n = 337 
LAC	and	IgG 3.8	(2.5‐5.9)
n = 138
4.7	(2.8‐7.6)
n = 118
3.3	(2.2‐4.9)
n = 148
5.9	(3.4‐10.5)
n = 104
LAC	and	IgM 4.5	(2.3‐8.7)
n = 64
3.5	(2.1‐5.8)
n = 93
3.5	(2.0‐6.3)
n = 77
3.6	(2.1‐6.3)
n = 83
IgG and IgM 3.3	(1.7‐6.2)
n = 60
5.8	(2.8‐11.9)
n = 65
2.6	(1.6‐4.5)
n = 78
7.1	(3.0‐16.7)
n = 52
LAC	and	IgG	and	IgM 6.4	(2.7‐15.2)
n = 48
6.2	(2.8‐13.8)
n = 54
5.5	(2.6‐11.8)
n = 56
9.6	(3.4‐27.1)
n = 46
Note: Odds	ratios	were	calculated	in	a	subpopulation	of	853	patients	consisting	of	thrombotic	APS	(n	=	259),	non‐APS	thrombosis	(n	=	204),	AID	
controls	(n	=	196),	and	controls	(n	=	194).
Odds	ratios	(OR)	are	shown	with	their	respective	95%	confidence	interval.
IgG	antibodies,	aCL,	and/or	aβ2GPI	IgG	antibodies;	IgM	antibodies,	aC,L	and/or	aβ2GPI	IgM	antibodies;	LAC,	lupus	anticoagulant.
TA B L E  6  Additional	value	of	aCL	and	aβ2GPI	IgM	antibodies	in	pregnancy	morbidity
 BioPlex®2200 Phadia® AcuStar® QUANTA Lite® ELISA
LAC	and/or	IgG	and/or	IgM 5.1	(3.4‐7.7)
n = 181
4.9	(3.2‐7.4)
n = 213
5.3	(3.5‐8.0)
n = 195
6.6	(4.3‐10.0)
n = 193
LAC	and	IgG 3.3	(1.9‐5.6)
n = 62
3.7	(2.0‐6.8)
n = 50
2.5	(1.5‐4.2)
n = 67
4.3	(2.2‐8.6)
n = 39
LAC	and	IgM 3.5	(1.5‐8.3)
n = 23
3.4	(1.7‐6.4)
n = 41
2.7	(1.3‐5.6)
n = 33
2.7	(1.4‐5.5)
n = 35
IgG and IgM 3.8	(1.7‐8.2)
n = 29
6.5	(2.9‐14.3)
n = 33
2.7	(1.4‐5.2)
n = 39
8.0	(3.1‐20.2)
n = 26
LAC	and	IgG	and	IgM 5.9	(2.1‐16.9)
n = 18
5.6	(2.3‐13.9)
n = 24
4.9	(2.0‐12.3)
n = 22
8.7	(2.8‐26.6)
n = 19
Note: Odds	ratios	were	calculated	in	a	subpopulation	of	483	patients	consisting	of	obstetric	APS	(n	=	122),	non‐APS	obstetric	(n	=	33),	female	AID	
controls	(n	=	158),	and	female	controls	(n	=	170).
Odds	ratios	(OR)	are	shown	with	their	respective	95%	confidence	interval.
IgG	antibodies,	aCL,	and/or	aβ2GPI	IgG	antibodies;	IgM	antibodies,	aCL,	and/or	aβ2GPI	IgM	antibodies;	LAC,	lupus	anticoagulant.
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risk	of	thrombosis.39	We	found	that	combined	positivity	for	LAC	and	
IgG	as	well	as	combined	positivity	for	LAC	and	IgM	was	significantly	
associated	with	thrombosis.	However,	in	two	out	of	four	solid	phase	
assays	OR	of	combined	LAC	and	IgG	aCL	or	aβ2GPI	was	higher	than	
positivity	for	LAC	and	IgM	aCL	or	aβ2GPI.	Within	pregnancy	mor‐
bidity,	 combined	 positivity	 for	 LAC	 and	 IgG	 or	 positivity	 for	 LAC	
and	 IgM	did	not	 increase	 the	OR	compared	 to	 the	current	criteria	
aPL‐panel.	Combined	positivity	for	LAC,	IgG,	and	IgM	was	more	as‐
sociated	with	pregnancy	morbidity	than	the	current	aPL‐panel	with	
three	out	of	the	four	tested	solid	phase	assays.
Diagnosis	of	APS	 is	dependent	on	 laboratory	 tests	detecting	
aPL	 antibodies.10,14,40	 Currently	 no	 gold	 standard	 exists	 for	 the	
detection	of	 aPL	antibodies.	 Solid	phase	assays	 are	poorly	 stan‐
dardized	and	many	studies	have	shown	that	different	results	are	
obtained	by	measuring	the	same	sample.10,14	 In	addition,	studies	
have	 shown	 that	 solid	 phase	 assays	 are	 associated	 with	 a	 large	
inter‐laboratory	variation.10,41	 In	order	 to	be	 independent	of	 the	
solid	phase	assay	used	and	minimize	the	interlaboratory	and	inter‐
individual	variation	in	aPL	detection,	a	single	operator	performed	
all	 assays	 within	 one	 laboratory.	 Although	 we	 demonstrated	 a	
largely	 similar	 clinical	 performance	 for	 all	 platforms,	 these	 data	
indicate	that	results	for	single	parameters	may	vary	between	plat‐
forms.	One	 of	 the	 four	 tested	 solid	 phase	 assays	was	 unable	 to	
demonstrate	a	significant	association	between	IgG	aCL	or	aβ2GPI	
antibodies	and	pregnancy	morbidity	within	a	multivariate	model,	
while	IgG	aCL	or	aβ2GPI	was	an	independent	variable	within	the	
other	tested	solid	phase	assays.	 In	addition,	combinations	of	 IgG	
and	 IgM	 showed	 higher	 variation	 of	 OR	 among	 the	 solid	 phase	
assays.	Combined	positivity	for	LAC,	IgG	and	IgM	aCL	or	aβ2GPI	
antibodies	was	highly	associated	with	thrombosis	and	pregnancy	
morbidity.	 However,	 calculated	 OR	 varied	 strongly	 among	 solid	
phase	assays,	accompanied	with	wide	95%	confidence	intervals.
In	conclusion,	 in	a	large	multicenter	study	aCL	and	aβ2GPI	IgM	
antibodies	 were	 significantly	 correlated	 with	 clinical	 features	 of	
APS.	However,	IgM	is	only	independently	associated	with	pregnancy	
morbidity	and	not	with	thrombosis.	Altogether,	our	data	support	the	
usage	 of	 two	 separate	 decision	 trees	 for	 thrombosis	 versus	 preg‐
nancy	morbidity,	in	which	aCL	and	aβ2GPI	IgM	is	tested	in	women	
suspected	of	obstetric	APS	but	not	in	patients	suspected	of	throm‐
botic	APS	(Figure	2A‐B).	However,	IgM	aPL	might	be	useful	as	a	sec‐
ond‐line	test	to	improve	thrombotic	risk	stratification	in	LAC‐	and/or	
IgG‐positive	patients	(Figure	2A).
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